Methotrexate

Methotrexate

• CAS Number: 59-05-2
• UNSPSC Description: Methotrexate (Amethopterin), an antimetabolite and antifolate agent, inhibits the enzyme dihydrofolate reductase, thereby preventing the conversion of folic acid into tetrahydrofolate, and inhibiting DNA synthesis. Methotrexate, also an immunosuppressant and antineoplastic agent, is used for the research of rheumatoid arthritis and a number of different cancers (such as acute lymphoblastic leukemia)[1][2][3].
• Target Antigen: ADC Cytotoxin; Antifolate; Apoptosis; Bacterial; DNA/RNA Synthesis
• Type: ADC Related
• Related Pathways: Antibody-drug Conjugate/ADC Related;Anti-infection;Apoptosis;Cell Cycle/DNA Damage
• Applications: Cancer-programmed cell death
• Field of Research: Cancer; Inflammation/Immunology
• Assay Protocol: https://www.medchemexpress.com/Methotrexate.html
• Solubility: DMSO : ≥ 50 mg/mL
• Smiles: NC1=NC(N)=C2C(N=CC(CN(C)C3=CC=C(C(N[C@@H](CCC(O)=O)C(O)=O)=O)C=C3)=N2)=N1
• Molecular Weight: 454.44
• References & Citations: [1]Tian H, et al. Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis. Bull NYU Hosp Jt Dis. 2007;65(3):168-73.|[2]Swierkot J, et al. Methotrexate in rheumatoid arthritis. Pharmacol Rep. 2006 Jul-Aug;58(4):473-92.|[3]Ehab Tousson, et al. The Effect of L-carnitine on Amethopterin-induced Toxicity in Rat Large Intestine.|[4]Banji D, et al. Evaluation of the concomitant use of methotrexate and curcumin on Freund's complete adjuvant-induced arthritis and hematological indices in rats. Indian J Pharmacol. 2011;43(5):546-550.Acta Pharmacol Sin. 2021 Jan;42(1):108-114.|Anticancer Res. 2024 Jul;44(7):2787-2792.|Anticancer Res. 2024 Oct;44(10):4213-4218.|Arthritis Res Ther. 2022 Jan 19;24(1):27.|Biochem Biophys Rep. December 2021, 101177.|Biomed Pharmacother. 2024 Jul 19:178:117167.|Biotechnol Bioeng. 2021 Sep 3.|Cancers (Basel). 2022 Oct 19;14(20):5127.|Cancers. 2019 Oct 25;11(11):1654.|Cell Death Dis. 2020 Nov 12;11(11):976.|Cell Death Dis. 2024 May 20;15(5):349.|Cell Rep Methods. 2023 Oct 23;3(10):100599.|Commun Biol. 2022 Jun 23;5(1):619.|Dis Model Mech. 2023 Mar 2;dmm.049769.|EMBO Mol Med. 2022 Feb 17;e14552.|Eur J Pharmacol. 2023 Nov 10:961:176162.|Int Immunopharmacol. 2023 Feb;115:109689.|Int Immunopharmacol. 2023 Nov 15;125(Pt B):111175.|Int Immunopharmacol. 2024 May 4:134:112183.|J Adv Res. 2024 Oct 5:S2090-1232(24)00432-6.|J Biol Chem. 2019 Dec 27;294(52):20084-20096. |J Bone Oncol. October 2021, 100391.|J Clin Invest. 2023 May 30;e169993.|J Mol Med (Berl). 2019 Aug;97(8):1183-1193.|J Nanobiotechnology. 2024 Mar 3;22(1):89.|J Pharm Anal. 7 August 2022.|Micromachines. 2021 Jun 10;12(6):681.|Mol Cancer. 2024 Apr 29;23(1):86.|Mol Cancer. 2024 Jan 10;23(1):12.|Oncotarget. 2017 Dec 2;8(68):112313-112329.|Patent. US20170128439A1.|Phytomedicine. 2022 Jun;100:154068.|Plasma Process Polym. 2021 Feb 12.|Queen’s University. Department of Biomedical Molecular Sciences. 2021 Oct.|Research Square Preprint. 2023 Dec 1.|Research Square Preprint. 2023 Dec 4.|Sci Rep. 2018 Jun 21;8(1):9472. |Sci Rep. 2024 Oct 31;14(1):26224.|Small. 2022 Jul;18(30):e2202337.|Toxicology. 2020 May 15;437:152445.|Sci Data. 2024 Sep 19.
• Shipping Conditions: Room Temperature
• Clinical Information: Launched